Louisiana State Employees Retirement System decreased its position in Eli Lilly and Co (NYSE:LLY) by 3.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 58,700 shares of the company’s stock after selling 1,800 shares during the quarter. Louisiana State Employees Retirement System’s holdings in Eli Lilly and were worth $4,958,000 at the end of the most recent reporting period.
Several other institutional investors have also recently made changes to their positions in the company. Acrospire Investment Management LLC raised its position in Eli Lilly and by 16.7% during the second quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock valued at $115,000 after buying an additional 200 shares during the period. MPS Loria Financial Planners LLC acquired a new position in Eli Lilly and during the second quarter valued at $128,000. San Francisco Sentry Investment Group CA acquired a new position in Eli Lilly and during the second quarter valued at $129,000. Willingdon Wealth Management acquired a new position in Eli Lilly and during the third quarter valued at $138,000. Finally, Wealthcare Advisory Partners LLC acquired a new position in Eli Lilly and during the third quarter valued at $142,000. Institutional investors and hedge funds own 76.35% of the company’s stock.
Shares of Eli Lilly and Co (NYSE:LLY) traded down $1.55 during midday trading on Tuesday, hitting $85.43. The stock had a trading volume of 2,059,646 shares, compared to its average volume of 2,741,344. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.03 and a current ratio of 1.38. The firm has a market cap of $94,530.00, a price-to-earnings ratio of 40.68, a price-to-earnings-growth ratio of 1.63 and a beta of 0.35. Eli Lilly and Co has a fifty-two week low of $74.00 and a fifty-two week high of $89.09.
Eli Lilly and (NYSE:LLY) last issued its quarterly earnings data on Tuesday, October 24th. The company reported $1.05 EPS for the quarter, beating the Zacks’ consensus estimate of $1.03 by $0.02. The business had revenue of $5.66 billion for the quarter, compared to analyst estimates of $5.52 billion. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The firm’s revenue for the quarter was up 9.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.88 EPS. analysts predict that Eli Lilly and Co will post 4.22 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 9th. Stockholders of record on Thursday, February 15th will be issued a dividend of $0.5625 per share. This is a positive change from Eli Lilly and’s previous quarterly dividend of $0.52. The ex-dividend date of this dividend is Wednesday, February 14th. This represents a $2.25 dividend on an annualized basis and a dividend yield of 2.63%. Eli Lilly and’s dividend payout ratio is currently 99.05%.
In related news, SVP Jeffrey N. Simmons sold 12,500 shares of the stock in a transaction that occurred on Monday, December 11th. The stock was sold at an average price of $86.46, for a total transaction of $1,080,750.00. Following the completion of the sale, the senior vice president now owns 124,522 shares in the company, valued at approximately $10,766,172.12. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Lilly Endowment Inc sold 200,000 shares of the stock in a transaction that occurred on Wednesday, December 13th. The shares were sold at an average price of $88.20, for a total value of $17,640,000.00. Following the sale, the insider now owns 123,084,104 shares of the company’s stock, valued at approximately $10,856,017,972.80. The disclosure for this sale can be found here. In the last three months, insiders have sold 251,088 shares of company stock worth $22,041,236. 0.20% of the stock is currently owned by insiders.
LLY has been the topic of several recent analyst reports. Berenberg Bank reissued a “buy” rating and set a $98.00 price target on shares of Eli Lilly and in a research report on Thursday, October 26th. Zacks Investment Research raised Eli Lilly and from a “hold” rating to a “buy” rating and set a $95.00 price target on the stock in a research report on Thursday, October 26th. Piper Jaffray Companies reissued a “buy” rating and set a $105.00 price target on shares of Eli Lilly and in a research report on Friday, October 13th. Goldman Sachs Group reissued a “buy” rating and set a $95.00 price target (up from $92.00) on shares of Eli Lilly and in a research report on Thursday, October 5th. Finally, Cowen reissued a “buy” rating and set a $95.00 price target on shares of Eli Lilly and in a research report on Wednesday, October 4th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and nine have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $92.75.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.